Paul Choi
Stock Analyst at Goldman Sachs
(3.58)
# 864
Out of 5,042 analysts
111
Total ratings
52.11%
Success rate
6.27%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Downgrades: Sell | $8 → $6 | $9.21 | -34.85% | 4 | Oct 15, 2025 | |
| LNTH Lantheus Holdings | Downgrades: Neutral | $110 → $77 | $56.06 | +37.35% | 2 | Oct 8, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Neutral | $20 | $15.18 | +31.75% | 1 | Sep 25, 2025 | |
| EXEL Exelixis | Initiates: Buy | $47 | $38.72 | +21.38% | 1 | Sep 17, 2025 | |
| AMRN Amarin Corporation | Maintains: Sell | $7 → $12 | $19.72 | -39.15% | 9 | Jun 25, 2025 | |
| URGN UroGen Pharma | Maintains: Neutral | $16 → $3 | $18.97 | -84.19% | 4 | May 22, 2025 | |
| GOSS Gossamer Bio | Maintains: Buy | $7 → $8 | $2.48 | +222.58% | 6 | May 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $10 → $5 | $13.53 | -63.05% | 10 | May 2, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $60 → $52 | $40.76 | +27.58% | 2 | Apr 17, 2025 | |
| VIR Vir Biotechnology | Maintains: Buy | $28 → $21 | $5.98 | +251.17% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $12 | $13.03 | -7.90% | 3 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $2.71 | +10.70% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $12 → $10 | $10.38 | -3.66% | 4 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $202.00 | +11.39% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $42 | $66.40 | -36.75% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 → $60 | $57.83 | +3.75% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $14.70 | +29.25% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $38.93 | -17.80% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $54.26 | -7.85% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $4.07 | +366.83% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $400 → $50 | $10.83 | +361.68% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.56 | +1,502.56% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $16.60 | +924.10% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $5.23 | +52.96% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $144.00 | -6.25% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $60.10 | +399.17% | 2 | Mar 30, 2020 |
Arvinas
Oct 15, 2025
Downgrades: Sell
Price Target: $8 → $6
Current: $9.21
Upside: -34.85%
Lantheus Holdings
Oct 8, 2025
Downgrades: Neutral
Price Target: $110 → $77
Current: $56.06
Upside: +37.35%
Edgewise Therapeutics
Sep 25, 2025
Initiates: Neutral
Price Target: $20
Current: $15.18
Upside: +31.75%
Exelixis
Sep 17, 2025
Initiates: Buy
Price Target: $47
Current: $38.72
Upside: +21.38%
Amarin Corporation
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $19.72
Upside: -39.15%
UroGen Pharma
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $18.97
Upside: -84.19%
Gossamer Bio
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $2.48
Upside: +222.58%
Phathom Pharmaceuticals
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $13.53
Upside: -63.05%
Xenon Pharmaceuticals
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $40.76
Upside: +27.58%
Vir Biotechnology
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $5.98
Upside: +251.17%
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $13.03
Upside: -7.90%
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $2.71
Upside: +10.70%
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $10.38
Upside: -3.66%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $202.00
Upside: +11.39%
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $66.40
Upside: -36.75%
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $57.83
Upside: +3.75%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $14.70
Upside: +29.25%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $38.93
Upside: -17.80%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $54.26
Upside: -7.85%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $4.07
Upside: +366.83%
Jun 27, 2023
Maintains: Sell
Price Target: $400 → $50
Current: $10.83
Upside: +361.68%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.56
Upside: +1,502.56%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $16.60
Upside: +924.10%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $5.23
Upside: +52.96%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $144.00
Upside: -6.25%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $60.10
Upside: +399.17%